Chartwell Investment Partners LLC purchased a new position in shares of Blueprint Medicines Corp (NASDAQ:BPMC) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 19,556 shares of the biotechnology company’s stock, valued at approximately $1,565,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. BlueMountain Capital Management LLC acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $140,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Blueprint Medicines by 24.2% during the 4th quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,000 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 390 shares during the last quarter. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Blueprint Medicines during the 4th quarter worth $140,000. Pacer Advisors Inc. acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth $286,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Blueprint Medicines by 16.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,255 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 594 shares during the last quarter.
NASDAQ BPMC opened at $77.70 on Tuesday. The company has a quick ratio of 8.29, a current ratio of 8.29 and a debt-to-equity ratio of 0.03. The firm has a market cap of $3.55 billion, a P/E ratio of -14.42 and a beta of 1.62. Blueprint Medicines Corp has a 1 year low of $44.58 and a 1 year high of $91.00.
Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($1.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.76) by ($0.07). The firm had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.77 million. Blueprint Medicines had a negative return on equity of 46.58% and a negative net margin of 531.53%. Blueprint Medicines’s quarterly revenue was down 36.7% on a year-over-year basis. During the same period in the prior year, the company posted ($1.23) earnings per share. On average, equities research analysts expect that Blueprint Medicines Corp will post -7.13 earnings per share for the current year.
In other Blueprint Medicines news, insider Ariel Hurley sold 415 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $85.55, for a total value of $35,503.25. Following the completion of the sale, the insider now directly owns 415 shares of the company’s stock, valued at approximately $35,503.25. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Kate Haviland sold 21,644 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $85.05, for a total transaction of $1,840,822.20. Following the completion of the sale, the chief operating officer now directly owns 20,018 shares of the company’s stock, valued at $1,702,530.90. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 44,359 shares of company stock valued at $3,798,843. 3.15% of the stock is owned by insiders.
Several research analysts have recently commented on BPMC shares. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Thursday, March 28th. BidaskClub downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 6th. ValuEngine downgraded shares of Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Zacks Investment Research raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. Finally, Wedbush reaffirmed an “outperform” rating and set a $103.00 price objective on shares of Blueprint Medicines in a report on Monday, January 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Blueprint Medicines has a consensus rating of “Buy” and an average price target of $105.00.
ILLEGAL ACTIVITY NOTICE: “19,556 Shares in Blueprint Medicines Corp (BPMC) Acquired by Chartwell Investment Partners LLC” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2019/04/16/19556-shares-in-blueprint-medicines-corp-bpmc-acquired-by-chartwell-investment-partners-llc.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: What are the qualifications of a portfolio manager?
Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Corp (NASDAQ:BPMC).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.